5Gralla RJ, Osoba D, Krismg, et al. Recommendations for the use of anti emetics : evidence-based, clinical practice guidelines[J] .J Clin Oncol, 1999, 17(9): 2971-2994.
7Apfel CC, Heidrich FM,Jukar-Rao S, et al. Evidence-based analysis of risk factors for postoperative nausea and vomiting[J] . BrJ Anaesth, 2012, 109(5): 742-753.
8Warr DG, Grunberg SM, Gralla RJ, et al. The oral NK 1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting- Pooled data from 2 randomised, double-blind, placebo controlled trials[J]. EurJ Cancer, 2005, 41(9): 1278-1285.
9Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron[J]. Ann Oncol, 2003, 14 ( 10) : 1570-1577.
10Eisenberg P, Figueroa- VadilloJ, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel SsH'L, receptor antagonist[J]. Cancer, 2003, 98( 11) : 2473-2482.
